控瘤治疗对儿童及青少年肿瘤患者卵巢功能的影响

doi:10.12372/jcp.2025.24e0598

摘要/Abstract

摘要：

近年来，随着控瘤治疗方案的不断改善，儿童及青少年肿瘤患者长期生存率显著提高。因此其远期生存质量逐渐得到重视，尤其是对于女性患儿，由于生育需求，内分泌生殖问题更是备受关注。控瘤治疗可能导致卵巢功能不全，影响青春期发育、生殖功能等，目前尚缺乏研究系统性地阐述控瘤治疗对患儿卵巢功能的影响及机制。本研究根据已有文献资料，总结控瘤治疗对儿童及青少年卵巢功能的影响、作用机制以及保护措施，论述目前此研究领域的局限性和未来突破点，期望能促进控瘤治疗策略的完善，保留患儿的生殖功能，提高其生存质量。

关键词: 控瘤治疗, 卵巢功能, 机制, 保护措施, 儿童, 青少年

Abstract:

In recent years, antineoplastic therapy have been continuously improved, and the long-term survival rate of children and adolescents with tumor has been significantly increased. Therefore, the long-term quality of life has been paid more and more attention, especially for female children and adolescents. Due to fertility requirements, endocrine and reproductive problems have attracted much attention. Antineoplastic therapy may lead to ovarian insufficiency, affecting pubertal development and reproductive function. There is currently a lack of research that systematically describes the mechanisms by which antineoplastic therapy affects the ovarian function of pediatric patients. Based on the existing literature, this study summarizes the effects and mechanisms of antineoplastic therapy on ovarian function in children and adolescents, concludes the measures to reserve ovarian function, and discusses the limitations and future breakthroughs in this field. It is expected to promote the improvement of antineoplastic therapy strategies, retain children and adolescents’ reproductive function, and enhance their quality of life.

Key words: antineoplastic therapy, ovarian function, mechanism, protective measure, child, adolescents

王敏, 王珊. 控瘤治疗对儿童及青少年肿瘤患者卵巢功能的影响[J]. 临床儿科杂志, 2025, 43(4): 306-311.

WANG Min, WANG Shan. The effect of antineoplastic therapy on ovarian function of children and adolescents[J]. Journal of Clinical Pediatrics, 2025, 43(4): 306-311.

参考文献 40

[1]	National Cancer Institute. SEER Cancer Statistics Review (CSR) 1975-2014[EB/OL]. [2024-06-11]. https://seer.cancer.gov/archive/csr/1975_2014/index.html.
[2]	Wallace WH, Kelsey TW, Morrison D, et al. Live birth and maternity outcome in childhood and adolescent cancer survivors under 18 years at diagnosis: a 40-year population-based cohort study[J]. Br J Cancer, 2024, 131(8): 1309-1319.
[3]	Spears N, Lopes F, Stefansdottir A, et al. Ovarian damage from chemotherapy and current approaches to its protection[J]. Hum Reprod Update, 2019, 25(6): 673-693. doi: 10.1093/humupd/dmz027 pmid: 31600388
[4]	European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L, Davies M, et al. ESHRE Guideline: management of women with premature ovarian insufficiency[J]. Hum Reprod, 2016, 31(5): 926-937.
[5]	Appiah LC. Fertility preservation for adolescents receiving cancer therapies[J]. Clin Obstet Gynecol, 2020, 63(3): 574-587. doi: 10.1097/GRF.0000000000000547 pmid: 32649323
[6]	Drechsel KCE, Pilon MCF, Stoutjesdijk F, et al. Reproductive ability in survivors of childhood, adolescent, and young adult Hodgkin lymphoma: a review[J]. Hum Reprod Update, 2023, 29(4): 486-517. doi: 10.1093/humupd/dmad002 pmid: 36779325
[7]	Chow EJ, Stratton KL, Leisenring WM, et al. Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort[J]. Lancet Oncol, 2016, 17(5): 567-576. doi: 10.1016/S1470-2045(16)00086-3 pmid: 27020005
[8]	van Santen HM, van de Wetering MD, Bos AME, et al. Reproductive complications in childhood cancer survivors[J]. Pediatr Clin North Am, 2020, 67(6): 1187-1202.
[9]	van der Kooi ALF, van Dijk M, Broer L, et al. Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function[J]. Hum Reprod, 2021, 36(4): 1120-1133.
[10]	Brooke RJ, Im C, Wilson CL, et al. A high-risk haplotype for premature menopause in childhood cancer survivors exposed to gonadotoxic therapy[J]. J Natl Cancer Inst, 2018, 110(8): 895-904. doi: 10.1093/jnci/djx281 pmid: 29432556
[11]	Thomas-Teinturier C, El Fayech C, Oberlin O, et al. Age at menopause and its influencing factors in a cohort of survivors of childhood cancer: earlier but rarely premature[J]. Hum Reprod, 2013, 28(2): 488-495.
[12]	Kalich-Philosoph L, Roness H, Carmely A, et al. Cyclophosphamide triggers follicle activation and "burnout"; AS101 prevents follicle loss and preserves fertility[J]. Sci Transl Med, 2013, 5(185): 185ra62.
[13]	Drechsel KCE, Broer SL, Stoutjesdijk FS, et al. Clinical and self-reported markers of reproductive function in female survivors of childhood Hodgkin lymphoma[J]. J Cancer Res Clin Oncol, 2023, 149(15): 13677-13695.
[14]	Mulder RL, Font-Gonzalez A, Hudson MM, et al. Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group[J]. Lancet Oncol, 2021, 22(2): e45-e56.
[15]	Wu C, Wu T, Chen D, et al. The effects and mechanism of taxanes on chemotherapy-associated ovarian damage: A review of current evidence[J]. Front Endocrinol (Lausanne), 2022, 13: 1025018.
[16]	Elchuri SV, Patterson BC, Brown M, et al. Low anti-Müllerian hormone in pediatric cancer survivors in the early years after gonadotoxic therapy[J]. J Pediatr Adolesc Gynecol, 2016, 29(4): 393-399.
[17]	Bereket A. Endocrinologic consequences of pediatric posterior fossa tumours[J]. J Clin Res Pediatr Endocrinol, 2015, 7(4): 253-259. doi: 10.4274/jcrpe.2135 pmid: 26777035
[18]	Stillman RJ, Schinfeld JS, Schiff I, et al. Ovarian failure in long-term survivors of childhood malignancy[J]. Am J Obstet Gynecol, 1981, 139(1): 62-66. pmid: 7457523
[19]	Soejima T. Radiation therapy of cancer in the adolescent and young adult (AYA) generation[J]. Jpn J Radiol, 2023, 41(12): 1331-1334. doi: 10.1007/s11604-023-01461-8 pmid: 37440159
[20]	Anderson RA, Cameron D, Clatot F, et al. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review[J]. Hum Reprod Update, 2022, 28(3): 417-434. doi: 10.1093/humupd/dmac004 pmid: 35199161
[21]	Yu B, Fritz R, Vega M, et al. Dissociation of pubertal development abnormality and gonadal dysfunction in childhood cancer survivors[J]. J Adolesc Young Adult Oncol, 2020, 9(4): 490-495.
[22]	van den Berg MH, Overbeek A, Lambalk CB, et al. Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve[J]. Hum Reprod, 2018, 33(8): 1474-1488.
[23]	Ratanasrithong P, Benjapibal M. Pregnancy outcomes after conservative surgery for early-stage ovarian neoplasms[J]. Asian Pac J Cancer Prev, 2017, 18(8): 2083-2087.
[24]	Chen H, Xiao L, Li J, et al. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women[J]. Cochrane Database Syst Rev, 2019, 3(3): CD008018.
[25]	Makarovsky D, Kalechman Y, Sonino T, et al. Tellurium compound AS101 induces PC12 differentiation and rescues the neurons from apoptotic death[J]. Ann N Y Acad Sci, 2003, 1010: 659-666.
[26]	Rodgers RJ, Abbott JA, Walters KA, et al. Translational physiology of anti-Müllerian hormone: clinical applications in female fertility preservation and cancer treatment[J]. Front Endocrinol (Lausanne), 2021, 12: 689532.
[27]	Harden SV, Twyman N, Lomas DJ, et al. A method for reducing ovarian doses in whole neuro-axis irradiation for medulloblastoma[J]. Radiother Oncol, 2003, 69(2): 183-188. pmid: 14643956
[28]	Mendenhall NP, Taylor BW Jr, Marcus RB Jr, et al. The impact of pelvic recurrence and elective pelvic irradiation on survival and treatment morbidity in early-stage Hodgkin's disease[J]. Int J Radiat Oncol Biol Phys, 1991, 21(5): 1157-1165.
[29]	Rosenbrock J, Vásquez-Torres A, Mueller H, et al. Involved site radiotherapy extends time to premature menopause in infra-diaphragmatic female Hodgkin lymphoma patients - an analysis of GHSG HD14- and HD17-patients[J]. Front Oncol, 2021, 11: 658358.
[30]	Lv XJ, Cheng XL, Tu YQ, et al. Association between the location of transposed ovary and ovarian dose in patients with cervical cancer treated with postoperative pelvic radiotherapy[J]. Radiat Oncol, 2019, 14(1): 230.
[31]	Gay C, Raphael YR, Steers J, et al. Ovarian transposition before pelvic radiation therapy: spatial distribution and dose volume analysis[J]. Adv Radiat Oncol, 2021, 7(1): 100804.
[32]	Bhatia S, Pappo AS, Acquazzino M, et al. Adolescent and young adult (AYA) oncology, version 2.2024, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2023, 21(8): 851-880.
[33]	Lambertini M, Peccatori FA, Demeestere I, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2020, 31(12): 1664-1678. doi: 10.1016/j.annonc.2020.09.006 pmid: 32976936
[34]	Vogt C, Malhotra NR. Fertility preservation in children and adolescents: where we are and where we are going[J]. Curr Urol Rep, 2024, 25(7): 133-140. doi: 10.1007/s11934-024-01204-w pmid: 38727983
[35]	Gellert SE, Pors SE, Kristensen SG, et al. Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort[J]. J Assist Reprod Genet, 2018, 35(4): 561-570.
[36]	Shapira M, Dolmans MM, Silber S, et al. Evaluation of ovarian tissue transplantation: results from three clinical centers[J]. Fertil Steril, 2020, 114(2): 388-397. doi: S0015-0282(20)30322-8 pmid: 32605799
[37]	Cui X, Jing X. Stem cell-based therapeutic potential in female ovarian aging and infertility[J]. J Ovarian Res, 2024, 17(1): 171. doi: 10.1186/s13048-024-01492-3 pmid: 39182123
[38]	Shi L, Zhang Z, Deng M, et al. Biological mechanisms and applied prospects of mesenchymal stem cells in premature ovarian failure[J]. Medicine (Baltimore), 2022, 101(32): e30013.
[39]	Zhao YX, Chen SR, Su PP, et al. Using mesenchymal stem cells to treat female infertility: an update on female reproductive diseases[J]. Stem Cells Int, 2019, 2019: 9071720.
[40]	Ling L, Hou J, Wang Y, et al. Effects of low-intensity pulsed ultrasound on the migration and homing of human amnion-derived mesenchymal stem cells to ovaries in rats with premature ovarian insufficiency[J]. Cell Transplant, 2022, 31: 9636897221129171.